Summary: In his weekly clinical update, Dr. Griffin discusses the new risk assessment for the H5N1 avian flu viruses, the development of monoclonal antibody-based blocking ELISA for detecting SARS-CoV-2 exposure in animals, repeated antibiotic exposure and risk of hospitalization and death following COVID-19 infection, COVID-19 rebound study: a prospective cohort study to evaluate viral and symptom rebound differences in participants treated with Nirmatrelvir plus Ritonavir versus untreated controls, exaggerated blood pressure elevation in response to orthostatic challenge a post-acute sequelae of SARS-CoV-2 infection (PASC) after hospitalization, long term follow-up of a multicenter cohort of COVID-19 patients with pulmonary embolism, and risk of cardiovascular disease after COVID‐19 diagnosis among adults with and without diabetes. Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode New risk assessment for H5N1 avian flu viruses (CDC) Development of monoclonal antibody-based blocking ELISA for detecting SARS-CoV-2 exposure (Virology) Repeated antibiotic exposure and risk of hospitalization and death following COVID-19 infection (eClinicalMedicine) COVID-19 Rebound Study (CID) Exaggerated blood pressure elevation in response to orthostatic challenge (AN) Long term follow-up of a multicenter cohort of COVID-19 patients with pulmonary embolism (TR) Risk of Cardiovascular disease after COVID‐19 diagnosis among adults with and without Diabetes (JAHA) Contribute to our FIMRC fundraiser at PWB Letters read on TWiV 1025 Dr. Griffin’s COVID treatment summary (pdf) Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv
